跳至主要内容
临床试验/CTRI/2018/04/013319
CTRI/2018/04/013319招募中4 期

An Observational, Practice based, Open label, Prospective Non Comparative, Multicenter, Post Marketing Surveillance Study to Assess Safety and Tolerability of Minocycline Hydrochloride 100 mg Intravenous (I.V.) Injection in Indian Patients with Multi-Drug Resistant Gram (MDR) Negative Bacterial Infections.

Cipla Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
招募中
发起方
Cipla Ltd

研究概览

简要总结

暂无简介。

研究设计

研究类型
Pms

入排标准

入选标准

  • 1. Written signed and dated informed consent (patient or LAR)
  • 2. Either gender with age 18 years and above
  • 3. Patients with Multi-Drug Resistant (MDR) gram negative bacterial infection
  • 4. Documented bacteriological infection susceptible to Minocycline Hydrochloride.

排除标准

  • 1. Known hypersensitivity to Minocycline Hydrochloride or any of its components
  • 2. Patient unsuitable to participate in the study as per the discretion of investigator
  • 3. Pregnant or nursing females
  • 4. Any other condition in the opinion of the investigator would affect the safety of the patient if Minocycline Hydrochloride is administered.

研究者

发起方
Cipla Ltd

相似试验